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posed for the determination of lansoprazole (LAN) in bulk drug and in its capsule formulation.
The methods are based on the interaction of LAN in dichloromethane (DCM) with acidic sulfonph-
thalein dyes, namely, bromocresol purple (BCP) in method A and bromothylmol blue (BTB) in
method B to form stable, yellow-colored, ion-pair complexes peaking at 400 and 430 nm, respec-
tively. The parameters that affect the reaction were carefully optimized, and under the optimized
conditions, linear relationships were obtained in the ranges of 0.5–15.0 and 1.25–20.0 lg mL1
LAN for method A and method B, respectively. The molar absorptivity values are calculated to
be 2.10 · 104 and 1.50 · 104 L mol1 cm1 for method A and method B, respectively. The compo-
sition of the ion-pairs was found to be 1:1 by Job’s method of continuous variations and the con-
ditional stability constant (log Kf) of the complexes has been calculated. The proposed methods
were applied successfully to the determination of LAN in capsules as well as in spiked urine sample
with good accuracy and precision. The results obtained by the proposed methods were compared
favorably with those of the reference method.
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Lansoprazole (LAN), chemically known as 2-[[[3-methyl-4-
(2,2,2-triﬂuoroethoxy)pyridine-2-yl]methyl]sulﬁnyl]-1H-benz-
imidazole, is an important proton pump inhibitor that
suppresses gastric acid secretion by speciﬁc inhibition of the
gastric H+, K+ ATPase enzyme system at the secretory sur-
face of the gastric parietal cells (Parﬁtt, 1999). Like other pro-
ton-pump inhibitors, LAN blocks the enzyme in the wall of the
stomach that produces acid. By blocking the enzyme, the pro-
duction of acid is decreased, and this allows the stomach and
esophagus to heal. It is also used for treating gastroesophageal
reﬂux disease (GERD) and Zollinger-Ellison Syndrome.
388 O.Z. Devi et al.The assay of drug is listed in the monograph of the United
States Pharmacopoeia (USP) (2000) and British Pharmaco-
poeia (2009). USP describes a high performance liquid chro-
matographic method and BP recommends potentiometric
titration of LAN with NaOH in 4:1 ethanol:water mixture.
A review of the literature revealed that several methods have
been reported for the analysis of LAN, both in biological ﬂuids
and in pharmaceutical preparations. LAN in biological ﬂuids
has been determined mostly by chromatographic techniques
such as high-performance liquid chromatography (HPLC)
(Miura et al., 2004; Li et al., 2009; Hu et al., 2007; Borner
et al., 1997), high-performance thin layer chromatography
(HPTLC) (Pandya et al., 1997), ultra-performance liquid chro-
matography (UPLC) (Li et al., 2008) and liquid chromatogra-
phy/tandem mass spectrometry (LC–MS) (Song et al., 2008;
Wu et al., 2008). Other techniques like voltammetry (Radi,
2002), polarography (El-Enany et al., 2008) have also been em-
ployed for the assay of LAN in biological ﬂuids. For the quan-Table 1 Comparison of the performance characteristic of the existin
determination of LAN in pharmaceuticals.
Sl. No. Reagent/s used Methodology
1. Ceric ammonium sulfate with
(a) methyl orange and
(b) indigo carmine
(a) Pink color of methyl orange
measured at 520 nm
(b) Blue color of indigo carmine
measured at 610 nm
2. Copper(II)sulfate with
(a) neocuproine and
(b) bathocuproine
(a) Yellow colored complex
measured at 460 nm
(b) Orange-red colored complex
measured at 480 nm
3. Ceric ammonium sulfate and
iron(II) with
(a) orthophenanthroline and
(b) thiocyanate
(a) Iron(II)–orthophenanthroline
complex measured at 510 nm
(b) Iron(II)–thiocyanate complex
measured at 470 nm
4. Iron(III) with ferricyanide The resulting Prussian blue
colored product measured at 730
5. Bromate–bromide mixture
and iron(II) with
(a) thiocyanate and
(b) orthophenanthroline
(a) Iron(II)–thiocyanate complex
measured at 470 nm
(b) Iron(II)–orthophenanthroline
complex measured at 510 nm
6. (a) Acetyl chloride with CuSO4
(b) MBTH with ceric
ammonium sulfate
1. The yellow colored product w
measured at 478.5 nm
2. The red colored product
measured at 491.2 nm
7. Chloranilic acid as p acceptor Charge-transfer complex
measured at 520 nm
8. (a) DDQ as p acceptor
(b) Iodine as r acceptor
(c) Ternary complex formation
with eosin and copper(II)
The colored products
were measured at
(a) 457 nm
(b) 293 and 359 nm
(c) 549 nm
9. (a) BCP
(b) BTB
Resulting yellow colored ion-pai
complexes were
measured at 400 nm for BCP
and 430 nm for BTB
MBTH: 3-methyl-2-benzothiazolinone hydrazone; DDQ: 2,3-dichloro-5,6titation of LAN in pharmaceutical preparations, methods
based on several techniques like HPLC (Basavaiah et al.,
2006b; Prasanna Kumar Reddy et al., 2009; Patel et al.,
2009; Prasanna Reddy et al., 2010), HPTLC (Susheel et al.,
2007; Argekar and Kunjir, 1996), LC–MS (Cao et al., 2006)
capillary electrophoresis (Lin and Wu, 2005; Tivesten et al.,
1999), polarography (El-Enany et al., 2008; Ozkan et al.,
2003; Belal et al., 2004), voltammetry (Ozkan et al., 2003;
Radi, 2003), UV-spectrophotometry (Sherje et al., 2008; O¨zal-
tı´n, 1999; Wahbi et al., 2002), ﬂow-injection analysis with UV-
detection (Yeniceli et al., 2004) and kinetic spectrophotometry
(Rahman and Kashif, 2010; Rahman et al., 2006) have been re-
ported. Most of the reported procedures are not simple for
routine analysis and require expensive or sophisticated instru-
ments. Hence, it is always required to develop simple, fast,
inexpensive analytical methods that can be readily adopted
for routine analysis at a relatively low-cost to the different
requirements of analytical problems.g spectrophotometric methods with the proposed methods for the
Linear range
(lg mL1), and
molar absorptivity
(L mol1 cm1)
Remarks Reference
0.5–7.0
e= 3.0 · 104
0.25–3.0
e= 4.4 · 104
Sensitive but
involve multiple-step
reactions
Basavaiah et
al. (2007a)
0.3–3.6
e= 5.82 · 104
0.2–3.2
e= 7.17 · 104
Sensitive
but requires heating
on a boiling water bath
for 10 min
Akheel Ahmed
and Syeda
(2007)
2.5–30
e= 8.1 · 103
2.5–25
e= 1.5 · 104
Lengthy procedure
and also involve
multiple-step reactions
Basavaiah et
al. (2006a)
nm
0.2–3.6
e= 6.78 · 104
Sensitive but uses
a slow reaction
Akheel Ahmed
and Syeda
(2008)
0.5–4.0
e= 3.97 · 104
0.5–6.0
e= 3.07 · 104
Involve multiple-step
reactions
Basavaiah et al.
(2007b)
as 100–600
100–500
Less sensitive
and requires heating
at 100 C for 5 min
Meyyanathan
et al. (1997)
5.0–80
e= 3.45 · 103
Less sensitive Basavaiah et
al. (2006b)
(a) 100–900
(b) 14.8–66.5
(c) 36.9–166.1
Less sensitive and
requires heating for ternary
complex formation
Moustafa
(2000)
r (a) 0.5–15.0
(e= 2.1 · 104)
(b) 1.25–20.0
(e= 1.5 · 104)
Sensitive with wide
linear dynamic ranges, no
heating or extraction step, no
pH-adjustment, single step
reaction and inexpensive
instrumental setup
Present
methods
-dicyano-1,4-benzoquinone.
Quantitative determination of lansoprozole in capsules 389Visible spectrophotometry, because of its simplicity and
cost effectiveness, sensitivity and selectivity, fair accuracy, pre-
cision and easy access in most quality control laboratories, has
remained competitive in the area of chromatographic tech-
niques for pharmaceutical analysis. Visible spectrophotometric
methods based on diverse reactions have been reported for the
determination of LAN in pharmaceuticals (Basavaiah et al.,
2006a,b, 2007a,b; Akheel Ahmed and Syeda, 2007, 2008; Mey-
yanathan et al., 1997; Moustafa et al., 2000). Reported meth-
ods are based on redox (Basavaiah et al., 2007a), redox
followed by complexation (Akheel Ahmed and Syeda, 2007,
2008; Basavaiah et al., 2006a,b), bromination (Basavaiah
et al., 2007b), complexation and oxidative coupling (Meyyana-
than et al., 1997) and charge-transfer complex formation reac-
tion (Moustafa et al., 2000; Basavaiah et al., 2006b). However,
most of the reported visible spectrophotometric methods suffer
from one or the other disadvantage like narrow range of deter-
mination (Basavaiah et al., 2006a,b, 2007a,b; Akheel Ahmed
and Syeda, 2007), poor sensitivity (Meyyanathan et al., 1997;
Moustafa et al., 2000; Basavaiah et al., 2006b), use of heating
(Meyyanathan et al., 1997), strict pH control (Basavaiah et al.,
2007a), etc. as shown in Table 1. For the assay of LAN in bio-
logical ﬂuids no visible spectrophotometric method has ever
been reported. In this piece of work, two simple and sensitive
extraction-free spectrophotometric methods based on ion-pair
formation reaction are proposed for the determination of LAN
in pharmaceuticals and spiked human urine sample.
2. Experimental
2.1. Instrument
A Systronics model 106 digital spectrophotometer provided
with 1-cm matched quartz cells was used for all absorbance
measurements.
2.2. Materials
Pharmaceutical grade lansoprazole (LAN) was received from
Cipla Ltd., Bangalore, India. The following pharmaceutical
preparations were purchased from commercial sources in the
local market and subjected to analysis: Lan-30 and Lan-15
from Intas Pharmaceuticals, Dehradun, India; and Lanzol-30
and Lanzol-15 from Cipla Ltd., Sikkim, India.
2.3. Reagents and chemicals
All the reagents and solvents used were of analytical-reagent
grade.
BCP (0.2%, w/v) (Rolex Laboratory Reagent, Mumbai, In-
dia) and BTB (0.1%, w/v) (Loba Chemie, Mumbai, India)
solutions were prepared in dichloromethane (Merck, Mumbai,
India) and kept in the dark when not in use.
2.4. Stock standard solution of LAN
A stock standard solution (100 lg mL1 LAN) was prepared
by dissolving accurately weighed 10 mg of pure drug in DCM
and diluting to the mark with the same solvent in a 100 mL cal-
ibrated ﬂask. This solution was diluted appropriately with
DCM to get a working concentration of 25 lg mL1 LAN
for use in both the methods.2.5. Sample preparation
2.5.1. Capsules
Contents of 20 capsules were pooled, mixed, weighed accu-
rately and powdered. A portion of the powder equivalent to
5 mg LAN was accurately weighed and transferred into a
50 mL calibrated ﬂask, 30 mL of DCM was added and the
content was shaken thoroughly for 15–20 min to extract the
drug into the liquid phase; the volume was ﬁnally diluted to
the mark with the same solvent, mixed well and ﬁltered using
a Whatman No. 42 ﬁlter paper. An aliquot of the ﬁltrate
(100 lg mL1 in LAN) was diluted with DCM to get a work-
ing concentration of 25 lg mL1 in LAN.
2.5.2. Placebo
A placebo of the composition: talc (20 mg), starch (15 mg),
acacia (15 mg), methyl cellulose (20 mg), sodium citrate
(15 mg), magnesium stearate (20 mg) and sodium alginate
(15 mg) was made and its solution was prepared as described
under ‘‘capsules’’.
2.5.3. Synthetic mixture
To the placebo blank of the composition described above,
5 mg of LAN was added and homogenized, transferred to a
50 mL calibrated ﬂask and the solution was prepared as de-
scribed under ‘‘capsules’’.
2.6. Procedures for calibration curve
2.6.1. Method A (using BCP)
Aliquots of 0.1, 0.25, 0.5, 1.0, 2.0 and 3.0 mL LAN standard
solution in DCM (25 lg mL1) were measured accurately
and transferred into a series of 5 mL calibrated ﬂasks. To each
ﬂask, 1 mL of 0.2% BCP solution was added, diluted to the
mark with the same solvent and mixed well. The absorbance
of the resulting yellow color chromogen was measured at
400 nm against the reagent blank after 10 min.
2.6.2. Method B (using BTB)
Varying aliquots, 0.25, 0.5, 1.0, 2.0, 3.0 and 4.0 mL of
25 lg mL1 standard LAN solution in DCM were measured
accurately and transferred into a series of 5 mL calibrated
ﬂasks. To each ﬂask was added 1 mL of 0.1% BTB, the con-
tent was mixed well and diluted to the mark with the same sol-
vent. After 10 min, the absorbance of each solution was
measured at 430 nm against the reagent blank.
In both the methods, a standard curve was prepared by
plotting the increasing absorbance values versus concentra-
tions of LAN. A linear equation for the standard curve was
calculated by linear regression.
2.6.3. Procedure for stoichiometric ratio
In order to establish the mole ratio between LAN and dye-
stuffs used, Job’s method of continuous variations of equimo-
lar solutions was employed: 1.2957 · 104 M solution each of
LAN and BCP (method A); and 9.6094 · 105 M solution
each of LAN and BTB (method B) were prepared separately
in DCM. A series of solutions were prepared in which the total
volume of LAN and reagent was kept at 5 mL. The drug and
the reagent were mixed in various complementary proportions
(0:5, 1:4, 2:3, . . . , 5:0, inclusive) and the absorbance of the
390 O.Z. Devi et al.resultant ion-pair complex in each case was measured at
400 nm in method A and 430 nm in method B; and plotted
against the mole fraction of the drug, [drug]/([drug] + [dye]).
2.6.4. Procedure for analysis of urine samples
Fifteen milliliters of spiked human urine containing 5 mg of
LAN was transferred into a 125 mL separating funnel and ex-
tracted three times with 15 mL DCM and the lower organic
layer was collected in a beaker containing anhydrous sodium
sulfate. The water-free organic layer was transferred into a
dry beaker and the solvent evaporated on a hot water bath.
The dry residue was dissolved in DCM and transferred into
a 50 mL calibrated ﬂask, and diluted up to the mark with
the same solvent. The resulting solution equivalent to
100 lg mL1 LAN was diluted to get 25 lg mL1 LAN and
analyzed by following the procedures described earlier.
3. Results and discussion
The present work has adopted a well known extraction-free
ion-pair complex formation reaction (Abdine et al., 2002; Al-
Ghannam, 2006; Shahdousti et al., 2008; Manjunatha et al.,
2008), since, the structure of LAN features its basic nature.
The methods are based on the formation of yellow colored
ion-pair complex between the amino group of LAN with anio-
nic dyes of sulfonphthalein group via the protonated nitrogen
atom of the drug. Among the sulfonphthalein dyes, BCP and
BTB were found to give stable and sensitive yellow colored
ion-pair complexes with LAN in DCM medium. The reaction
behind the formation of yellow colored complex is that the lac-
toid ring present in sulfonphthalein dyes opens to convert the
dye into quinoidal derivative (Ashour et al., 2006), and the sul-
fonic acid present in quinoid body dissociates to negatively
charged dye. Finally, the anionic dyes form ion-pair complexes
with protonated LAN. In LAN, benzimidazole nitrogen is the
most vulnerable one to protonate when compared to otherNNH
N
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Scheme 1 The probablenitrogen atoms (Gupta et al., 2008). Each drug–dye complex
with two oppositely charged ions, behaves as a single unit held
together by weak electrostatic force of attraction (Harikrishna
et al., 2008). Based on these ﬁndings, the reaction pathway is
proposed to proceed as shown in Scheme 1.
3.1. Spectral characteristics
The ion-pair complexes of LAN-BCP and LAN-BTB showed
absorption maxima at 400 and 430 nm, respectively, where
the reagent blanks gave almost negligible absorbance
(Fig. 1). However, in all instances, the absorbance was mea-
sured at those kmax against a reagent blank prepared under
identical conditions.
3.2. Optimization of reaction conditions
The experimental conditions were established by varying one
variable and observing its effect on the absorbance of the col-
ored species.
3.2.1. Choice of the organic solvent
A number of organic solvents such as dichloromethane,
dichloroethane, acetonitrile, acetone, dioxane, dimethyl sulf-
oxide and carbon tetrachloride were examined to carry out
the experiments. Among these solvents, high sensitivity as well
as negligible blank absorbance was achieved in DCM medium.
Hence, DCM was selected as the suitable solvent to carry out
further investigations.
3.2.2. Effect of dye concentration
The inﬂuence of the concentration of BCP and BTB on the
intensity of the color formed at the selected wavelength was
studied by using 0.2% BCP in method A and 0.1% BTB in
method B. In method A, constant absorbance readings were
obtained when 0.5–2.0 mL of 0.2% BCP was used (Fig. 2)CH3
O
Br
Br
CH3
OH
CH3
O
BrSO3
NNH
NH
SO
CH3
O F
F
F
Br
CH3
OH
CH3
O
BrSO3
 ring)
+ H+
-
+
1:1 ion pair complex of LAN:BCP
-
reaction mechanism.
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Figure 1 Absorption spectra (10 lg mL1 LAN in method A
and 15 lg mL1 LAN in method B).
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Figure 2 Effect of dyes (10 lg mL1 LAN in method A and
15 lg mL1 LAN in method B).
0.0 0.2 0.4 0.6 0.8 1.0
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
A
bs
or
ba
nc
e
[LAN]/[LAN]+[BCP]
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
A
bs
or
ba
nc
e
[LAN]/[LAN]+[BTB]
a
b
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Hence, 1 mL of 0.2% BCP was ﬁxed in method A. In method
B, sensitivity as well as the blank absorbance was found to-
increase with increasing concentration of BTB as shown in
Fig. 2. Hence by considering minimum blank absorbance
as well as the sensitivity, 1 mL of 0.1% BCP was ﬁxed in
method B.
3.2.3. Effect of reaction time
The optimum reaction time for the development of color at
ambient temperature (25 ± 2 C) was studied and it was found
that complete color development was achieved after 10 min in
both the methods. The formed color was stable for at least
45 min in method A and 35 min in method B.3.3. Composition of ion-pair complexes
The composition of ion-pair complexes was established by
Job’s method of continuous variations using variable dye
and LAN concentrations. In both the cases, the drug–dye stoi-
chiometric ratio was found to be 1:1 as shown in Fig. 3.
3.4. Conditional stability constants (Kf) of the ion-pair
complexes
The conditional stability constants (Kf) of the ion-pair com-
plexes for LAN were calculated from the continuous variation
data using the following equation (Amin et al., 2007):
Kf ¼ A=Am½1 A=Amnþ2CMðnÞn
where A and Am are the observed maximum absorbance and
the absorbance value when all the drug present is associated,
respectively. CM is the molar concentration of drug at the max-
imum absorbance and n is the stoichiometry with which the
0
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Figure 4 Calibrations curves: (a) method A and (b) method B.
392 O.Z. Devi et al.dye ion associates with the drug. The log Kf values for LAN-
BCP and LAN-BTB ion-pair associates were 4.874 ± 0.678,
and 4.949 ± 0.842, respectively.
4. Method validation
The proposed methods were validated for linearity, sensitivity,
precision, accuracy, robustness, ruggedness, selectivity and
recovery according to the International Conference on Harmo-
nization (1996) guidelines.
4.1. Linearity and sensitivity
Under optimum conditions, linear relations were obtained be-
tween absorbance and concentration of LAN in the range of
0.5–15.0 lg mL1 in method A and 1.25–20.0 lg mL1 in
method B (Fig. 4). The calibration graph in each instance is de-
scribed by the equation:
Y ¼ aþ bX
(where Y= absorbance, a= intercept, b= slope and
X= concentration in lg mL1) obtained by the method of
least squares. Correlation coefﬁcient, intercept and slope for
the calibration data are summarized in Table 2. Sensitivity
parameters, such as apparent molar absorptivity and Sandell’s
sensitivity values, the limit of detection (LOD) and the limit ofTable 2 Sensitivity and regression parameters.
Parameter Method A Method B
kmax (nm) 400 430
Linear range (lg mL1) 0.5–15 1.25–20
Molar absorptivity (e) (L mol1 cm1) 2.1 · 104 1.5 · 104
Sandell sensitivitya (lg cm2) 0.018 0.025
Limit of detection (LOD) (lg mL1) 0.12 0.40
Limit of quantiﬁcation (LOQ) (lg mL1) 0.35 1.23
Regression equation, Yb
Intercept (a) 0.013 0.002
Slope (b) 0.053 0.039
Standard deviation of a (Sa) 0.126 0.021
Standard deviation of b (Sb) 0.01 0.001
Regression coeﬃcient (r) 0.998 0.996
a Limit of determination as the weight in lg mL1 of solution,
which corresponds to an absorbance of A= 0.001 measured in a
cuvette of cross-sectional area 1 cm2 and l= 1 cm.
b Y= a+ bX, where Y is the absorbance, X is concentration in
lg mL1, a is the intercept, b is the slope.quantiﬁcation (LOQ) are calculated as per the current ICH
guidelines (1996), which are compiled in Table 2 speak of the
sensitivity of the proposed methods. LOD and LOQ were cal-
culated according to the same guidelines using the formulae:
LOD ¼ 3:3r=b and LOQ ¼ 10r=b
where r is the standard deviation of ﬁve reagent blank determi-
nations and b is the slope of the calibration curve.
4.2. Precision and accuracy
Intra-day precision and accuracy of the proposed methods
were evaluated by replicate analysis (n= 7) of calibration
standards at three different concentration levels on the same
day. Inter-day precision and accuracy were determined by
assaying the calibration standards at the same concentration
levels on ﬁve consecutive days. Precision and accuracy were
based on the calculated relative standard deviation (RSD,
%) and relative error (RE, %) of the found concentration
compared to the theoretical one, respectively (Table 3).
4.3. Robustness and ruggedness
Method robustness was tested by making small incremental
changes in the volume of dyes and reaction time. To check
the ruggedness, an analysis was performed by four different
analysts; and on three different spectrophotometers by the
same analyst. The robustness and the ruggedness were checked
at three different drug levels. The intermediate precision, ex-
pressed as percent RSD, which is a measure of robustness
and ruggedness was within the acceptable limits as shown in
Table 4.
4.4. Selectivity
The proposed methods were tested for selectivity by placebo
and synthetic mixture analyses. A convenient aliquot of the
placebo solution was subjected to analysis according to the
recommended procedures. In both cases, there was no interfer-
ence by the inactive ingredients as indicated by the near blank
absorbance.
A separate experiment was performed with the synthetic
mixture. The analysis of synthetic mixture solution yielded per-
cent recoveries which were in the range of 103.7–109.7 with
standard deviation of 1.26–1.64 in both the cases. The results
of this study are presented in Table 5 indicating that the inac-
tive ingredients did not interfere in the assay. These results fur-
ther demonstrate the accuracy as well as the precision of the
proposed methods.
Table 3 Evaluation of intra-day and inter-day accuracy and precision.
Method LAN taken (lg mL1) Intra-day accuracy and precision (n= 7) Inter-day accuracy and precision (n= 7)
LAN found (lg mL1) % RE % RSD LAN found (lg mL1) % RE % RSD
Method A (using BCP) 5.0 4.91 1.80 1.92 5.14 2.80 2.05
10.0 10.21 2.09 1.65 9.73 2.69 1.91
15.0 14.77 1.53 1.87 15.37 2.47 2.11
Method B (using BTB) 5.0 4.87 2.59 1.36 4.86 2.79 1.63
10.0 9.75 2.54 1.98 10.29 2.90 2.15
15.0 15.35 2.34 1.06 14.61 2.61 2.03
RE: relative error; RSD: relative standard deviation.
Table 4 Robustness and ruggedness expressed as intermediate precision (% RSD).
Method LAN taken (lg mL1) Method robustness Method ruggedness
Parameter altered Inter-analysts’
RSD (%) (n= 4)
Inter-instruments’
RSD (%) (n= 3)
BCP (mL)a in method A
or BTB (mL)a in method B
RSD (%) (n= 3)
Reaction timeb
(min) RSD
(%) (n= 3)
Method A (using BCP) 5.0 1.97 1.45 1.35 2.36
10.0 1.73 1.62 1.03 2.29
15.0 2.01 1.39 1.11 2.42
Method B (using BTB) 5.0 1.93 1.56 0.97 2.39
10.0 1.97 1.28 1.16 2.28
15.0 1.61 1.35 0.99 2.37
a BCP and BTB volumes used were 0.8, 1.0 and 1.2 mL.
b The reaction times altered were 8, 10 and 12 min.
Table 5 Recovery of the drug from synthetic mixture.
Method LAN in synthetic
mixture taken
(lg mL1)
LAN recovereda
(percent ± SD)
Method A (using BCP) 5.0 109.7 ± 1.26
10.0 106.9 ± 1.57
15.0 105.2 ± 1.61
Method B (using BTB) 5.0 104.5 ± 1.43
10.0 106.2 ± 1.64
15.0 103.7 ± 1.57
a Mean value of ﬁve determinations.
Table 6 Recovery of the drug from spiked human urine.
Method LAN in spiked
human urine taken
(lg mL1)
LAN recovereda
(percent ± SD)
Method A (using BCP) 5.0 96.75 ± 1.31
10.0 95.62 ± 1.57
15.0 97.05 ± 1.47
Method B (using BTB) 5.0 96.79 ± 1.42
10.0 97.18 ± 1.38
15.0 95.99 ± 1.24
a Mean value of ﬁve determinations.
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The proposed methods were successfully applied to the deter-
mination of LAN in spiked urine sample with mean percent
recovery ± S.D. in the range of 95.62–97.18 (n= 5) ± 1.24–
1.57 in both the cases (Table 6). In order to evaluate the ana-
lytical applicability of the proposed methods to the quantiﬁca-
tion of LAN in commercial capsules, the results obtained by
the proposed methods were compared to those of the reference
method (British Pharmacopoeia, 2009) by applying Student’s
t-test for accuracy and F-test for precision at the 95% conﬁ-
dence level. The reference method involved the potentiometric
titration in which LAN in 4:1 ethanol:water mixture was ti-
trated against 0.1 M NaOH. The results (Table 7) show that
the Student’s t- and F-values at 95% conﬁdence level are less
than the theoretical values, which conﬁrmed that there is a
good agreement between the results obtained by the proposed
methods and the reference method with respect to accuracy
and precision.
4.6. Recovery studies
The accuracy and validity of the proposed methods were fur-
ther ascertained by performing recovery studies. Pre-analyzed
capsule powder was spiked with pure LAN at three concentra-
tion levels (50%, 100% and 150% of that in capsule powder)
and the total was found by the proposed methods. In both
the cases, the added LAN recovery percentage values ranged
between 98.79% and 105.6% with standard deviation between
Table 7 Results of analysis of capsules by the proposed methods.
Capsule brand name Label claim (mg/capsule) Founda (percent of label claim ± SD) (n= 5)
Reference method Method A (using BCP) Method B (using BTB)
Lan-15b 15 100.7 ± 0.94 98.84 ± 1.51 102.2 ± 1.46
t= 2.39 t= 1.97
F= 2.58 F= 2.41
Lanzol-15c 15 100.5 ± 1.09 98.67 ± 1.64 102.7 ± 1.68
t= 2.11 t= 2.50
F= 2.26 F= 2.38
Lan-30b 30 101.2 ± 0.87 102.3 ± 1.17 103.2 ± 1.58
t= 1.70 t= 2.57
F= 1.81 F= 3.29
Lanzol-30c 30 99.87 ± 1.02 98.07 ± 1.57 101.3 ± 1.63
t= 2.20 t= 1.71
F= 2.37 F= 2.55
The value of t (tabulated) at 95% conﬁdence level and for four degrees of freedom is 2.77.
The value of F (tabulated) at 95% conﬁdence level and for four degrees of freedom is 6.39.
a Mean value of ﬁve determinations.
b Intas Pharmaceuticals, Dehradun, India;
c Cipla Ltd., Sikkim, India.
Table 8 Accuracy assessment by recovery experiment.
Method Capsule studied LAN in
capsule (lg mL1)
Pure LAN added
(lg mL1)
Total found
(lg mL1)
Pure LAN recovereda
(percent ± SD)
Method A (using BCP) Lanzol-15 4.93 2.5 7.53 103.9 ± 1.31
4.93 5.0 10.17 104.8 ± 1.47
4.93 7.5 12.34 98.79 ± 1.17
Method B (using BTB) Lanzol-15 5.14 2.5 7.73 103.6 ± 1.54
5.14 5.0 10.42 105.6 ± 1.36
5.14 7.5 12.80 102.1 ± 1.68
a Mean value of three measurements.
394 O.Z. Devi et al.1.17 and 1.68 (Table 8) indicating that the recovery was good,
and that the co-formulated substance did not interfere in the
determination.
5. Conclusions
The present communication reports the ﬁrst spectrophotomet-
ric assay of LAN in biological ﬂuid. The methods are based on
well-characterized ion-pair complex formation reaction. The
methods are simple, rapid, sensitive, selective, cost-effective
and offer wide range of determination without the need for
extraction or heating, and also found to be the most sensitive
methods for LAN. Besides the simplicity and sensitivity of the
procedures, the relative cheapness of the apparatus and re-
agents demonstrates their advantageous characteristics. The
methods are also useful due to high tolerance limit for com-
mon excipients found in drug formulations. These merits cou-
pled with the use of simple and inexpensive instruments and
high selectivity of the methods recommend the use of these
methods in routine quality control laboratories.Acknowledgments
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